Back to today’s briefing

Story perspectives

FDA Approves N-803: Breakthrough for Bladder Cancer Treatment

2/15/2025

45 8

Summary

Story summary

Nogapendekin alfa inbakicept-pmln (N-803) has gained FDA approval as a groundbreaking treatment for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), showcasing a remarkable 55% complete response rate in just three months during the QUILT-3.032 trial. This advancement, alongside treatments like pembrolizumab and nadofaragene firadenovec, is revolutionizing personalized care for patients battling this challenging disease.

1 of 1

Story summary

Nogapendekin alfa inbakicept-pmln (N-803) has gained FDA approval as a groundbreaking treatment for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), showcasing a remarkable 55% complete response rate in just three months during the QUILT-3.032 trial. This advancement, alongside treatments like pembrolizumab and nadofaragene firadenovec, is revolutionizing personalized care for patients battling this challenging disease.